Patent EP0357581B1 successfully refreshed from Google Patents.
← Back to Patent Explorer
EP0357581B1 Expired / Lapsed EP ⏱️ 0.0 years remaining

Composition for the treatment of erectile dysfunction

Assignee: Amsu Ltd
•
Filing: 1989-08-31
•
Granted: 1993-07-28
•
Expires: 2009-08-31
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

No abstract record available.

Inventors

  • 👤 Nils G. Kock
  • 👤 Gerhard Lycke

Bibliographic Details

Application Number —
Jurisdiction EP
Data Source google_patents
Last Synchronized 2026-10-31 18:25
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/21; A61K31/557; A61K31/5575; A61K9/00; A61K9/0012; A61K9/0034; A61P; A61P13/00; A61P13/02; A61P15/00; A61P25/00; A61P25/02; A61P31/00; A61P31/04

Claims Analysis

Total Claims: 33
Claim 1
Independent Claim 41 words
A process for the preparation of a composition for treatment of erectile dysfunction via urethra, comprising dispersing of a lipophilic active substance selected from a-receptor blockers, vasoactive intestinal polypeptide, prostaglandins and nitroglycerine into a hydrophilic vehicle and optionally an antibacterial agent.
Claim 2
Dependent Claim 41 words
A process for the preparation of a composition for treatment of erectile dysfunction via urethra, comprising dispersing of a lipophilic active substance selected from a-receptor blockers, vasoactive intestinal polypeptide, prostaglandins and nitroglycerine into a hydrophilic vehicle and optionally an antibacterial agent.
Claim 3
Dependent Claim 23 words
A process according to Claim 1 for the preparation of a composition wherein the a-receptor blockers are selected from phentolamine, phenoxybenzamine and prazosine.
Claim 4
Dependent Claim 22 words
A process according to Claim 2 for the preparation of a composition, comprising phentolamine in an amount of at least 10 mg.
Claim 5
Dependent Claim 23 words
A process according to Claim 3 for the preparation of a composition, comprising phentolamine in an amount of 10-200 mg, preferably 50-60 mg.
Claim 6
Dependent Claim 22 words
A process according to Claim 2 for the preparation of a composition, comprising phenoxybenzamine in an amount of at least 50 mg.
Claim 7
Dependent Claim 23 words
A process according to Claim 5 for the preparation of a composition, comprising phenoxybenzamine in an amount of 50-300 mg, preferably 100-150 mg.
Claim 8
Dependent Claim 22 words
A process according to Claim 1 for the preparation of a composition, comprising nitroglycerine in an amount of at most 5 mg.
Claim 9
Dependent Claim 23 words
A process according to Claim 7 for the preparation of a composition, comprising nitroglycerine in an amount of 0.5-5 mg, preferably 0.5-1.5 mg.
Claim 10
Dependent Claim 34 words
A process according to Claim 1 for the preparation of a composition, comprising the active substance and optionally hydrophilic vehicle and optionally an antibacterial agent in an volume of 1-6 ml, generally 2-3 ml.
Claim 11
Dependent Claim 32 words
A process according to Claim 1 for the preparation of a composition, wherein the active substance is selected of at least 2 members: from a-receptor blockers, vasoactive intestinal polypeptide, prostaglandins and nitroglycerine.
Claim 12
Dependent Claim 23 words
A process according to Claim 1 for the preparation of a composition, wherein the active substance is selected from a-receptor blockers and nitroglycerine.
Claim 13
Dependent Claim 20 words
A process according to Claims 10 and 11 for the preparation of a composition, wherein the a-receptor blocker is phentolamine.
Claim 14
Dependent Claim 20 words
A process according to Claims 10 and 11 for the preparation of a composition, wherein the a-receptor blocker is phenoxybenzamine.
Claim 15
Dependent Claim 24 words
A process according to Claims 10, 11 and 12 for the preparation of a composition, wherein the a-receptor blocker is both phentolamine and phenoxybenzamine.
Claim 16
Dependent Claim 33 words
A process according to Claims 10-14 for the preparation of a composition, comprising the active substance in the amounts disclosed in Claims 3 to 8 and in the volume disclosed in Claim 9.
Claim 17
Dependent Claim 49 words
Use of a lipophilic active substance selected from a-receptor blockers, vasoactive intestinal polypeptide, prostaglandines and nitroglycerine, optionally together with a hydrophilic vehicle and optionally an antibacterial agent for the preparation of a medicament for the treatment of erectile dysfunction by administration of the medicament via urethra to corpora cavernosa.
Claim 18
Dependent Claim 49 words
Use of a lipophilic active substance selected from a-receptor blockers, vasoactive intestinal polypeptide, prostaglandines and nitroglycerine, optionally together with a hydrophilic vehicle and optionally an antibacterial agent for the preparation of a medicament for the treatment of erectile dysfunction by administration of the medicament via urethra to corpora cavernosa.
Claim 19
Dependent Claim 14 words
Use according to Claim 16 of a-receptor blockers selected from phentolamine, phenoxybenzamine and prazosine.
Claim 20
Dependent Claim 15 words
Use according to Claim 17 of phentolamine in an amount of at least 10 mg.
Claim 21
Dependent Claim 16 words
Use according to Claim 18 of phentolamine in an amount of 10-200 mg, preferably 50-60 mg.
Claim 22
Dependent Claim 15 words
Use according to claim 17 of phenoxybenzamine in an amount of at least 50 mg.
Claim 23
Dependent Claim 16 words
Use according to Claim 20 of phenoxybenzamine in an amount of 50-300 mg, preferably 100-150 mg.
Claim 24
Dependent Claim 15 words
Use according to Claim 16 of nitroglycerine in an amount of at most 5 mg.
Claim 25
Dependent Claim 16 words
Use according to Claim 22 of nitroglycerine in an amount of 0.5-5 mg, preferably 0.5-1.5 mg.
Claim 26
Dependent Claim 27 words
Use according to Claim 15 of the active substance and optionally hydrophilic vehicle and optionally an antibacterial agent in a volume of 1-6 ml, generally 2-3 ml.
Claim 27
Dependent Claim 23 words
Use according to Claim 16 of at least 2 members of the group consisting of a-receptor blockers, vasoactive intestinal polypeptide, prostaglandins and nitroglycerine.
Claim 28
Dependent Claim 18 words
Use according to Claims 16 and 25, wherein the active substance is selected from a-receptor blockers and nitroglycerine.
Claim 29
Dependent Claim 11 words
Use according to Claim 26, wherein the a-receptor blocker is phentolamine.
Claim 30
Dependent Claim 11 words
Use according to Claim 26, wherein the a-receptor blocker is phenoxybenzamine.
Claim 31
Dependent Claim 14 words
Use according to Claim 26, wherein the a-receptor blocker is both phentolamine and phenoxybenzamine.
Claim 32
Dependent Claim 27 words
Use according to Claims 25 to 29 of the active substance in the amounts disclosed in Claims 18 to 21 and the volume disclosed in Claim 24.
Claim 33
Dependent Claim 20 words
Use according to Claim 15, wherein the vehicle consists of e.g. macrogols and/or other fat free cream or ointment bases.

References Cited (Backward Citations)

No citation records indexed.

USPTO Annuity & Maintenance Windows

Maintenance schedule is calculated for granted US utility patents.

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag